ACTB and ovarian carcinoma: The simultaneous treatment of the UWB1.289, UWB1.289 + BRCA1, SKOV-3 and OVCAR-3 human ovarian cancer cells with 3-AB in combination with ASA-A, ASA-B or ASA-C induced a significant (p < 0.001) synergistic effect on the % increase of PARP1/ACTB mRNA cellular content, mostly in ASA-B and less in ASA-A combinations with 3-AB.